Treatment of Hypoactive Delirium and Outcome Measures (THDOM)
Hypoactive Delirium
About this trial
This is an interventional treatment trial for Hypoactive Delirium
Eligibility Criteria
Inclusion Criteria:
- Patients who fulfill criteria for delirium according to CAM and DOSS
- Patients in hospitalization who are not receiving treatment for delirium
- Patients without treatment with antipsychotics for any other reason
- Patients whose legally proxy accepts to participate
Exclusion Criteria:
- Patients who have received pharmacologic treatment for delirium
- Patients with a corrected QT interval prolongation
- Patients who receive antipsychotics for any other reason
- Patients in another age group
- Patients whose legally proxy does not accept to participate
- Patients with dementia
- Patients with Parkinson disease
- Patients with arrythmias
- Patients with language or hearing disorders that impede communication
- Patients hospitalized in the Intensive Care Unit
- Patients who are receiving benzodiazepines and anticholinergics
- Patients with dopamine agonists or antagonists
- Patients who develop a severe neurologic disease
Sites / Locations
- Department of Neurology and Psychiatry. Instituto Nacional de Ciencias Médicas y NutriciónRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Haloperidol and non-pharmacologic
Placebo and non-pharmacologic
Haloperidol 1.25mg PO q. d. during nine days Non-pharmacologic measures: A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
Placebo 1.25 mg PO q.d during nine days. Non-pharmacologic measures: A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)